Pappas Capital Announces the Passing of…

Life sciences innovation: The struggle to retain and attract investors

Biotech Showcase 2012 during the JP Morgan Healthcare Conference
January 11, 2012
San Francisco, CA

Panelists address ways to overcome funding obstacles for innovative life science programs and their investors.

A recent study by the NVCA reported that many venture capitalists are eliminating their investments in US life science companies altogether while others are shifting their focus to ex-US investments principally because of perceived regulatory obstacles.  Furthermore, with few exceptions, companies with early stage pipelines are not likely IPO candidates nor are they compelling targets for M&A transactions with big pharma. These trends paint a daunting picture for any life science company trying to advance their programs.  This panel, with Roger Longman of Real Endpoints; Polly Murphy, Pfizer; Arthur Pappas of Pappas Ventures;Barbara Fox, Avaxia Biologics; Evonne Sepsis, ESC Advisors; and Todd Sherer of Michael J. Fox Foundation, led by moderator Ellen Corenswet of Covington & Burling, discusses potential ways to address these obstacles on multiple levels for innovator companies as well as their investors.